Page last updated: 2024-11-03

probenecid and Granulocytic Leukemia

probenecid has been researched along with Granulocytic Leukemia in 1 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsimberidou, AM1
Paterakis, G1
Androutsos, G1
Anagnostopoulos, N1
Galanopoulos, A1
Kalmantis, T1
Meletis, J1
Rombos, Y1
Sagriotis, A1
Symeonidis, A1
Tiniakou, M1
Zoumbos, N1
Yataganas, X1

Other Studies

1 other study available for probenecid and Granulocytic Leukemia

ArticleYear
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Leukemia research, 2002, Volume: 26, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols;

2002